Clinical Trials

Bioclinica has introduced a specialized program for the adjudication of adverse events that could result from COVID-19 infection. Bioclinica's new program provides an out-of-the-box Clinical Endpoint Committee solution. This solution combines world-class medical expertise, an experienced adjudication management team,...

Catalent, a global leader in clinical supply services, welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating...

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark is the first company in...

CTI BioPharma Corp. initiated PRE-VENT, a Phase III study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358...

The COVID-19 pandemic has exposed some significant frailties in the physical clinical supply chain. As governments, medical professionals and life science organisations around the world direct their energy and resources to curtailing the pandemic, a challenge that requires attention,...

Researchers at Queen’s University Belfast are leading a UK-wide clinical trial, offering an innovative cell therapy treatment for COVID-19 patients with acute respiratory failure. This clinical trial, led by Professor Danny McAuley and Professor Cecilia O’Kane, both researchers from the...

Pfizer and BioNTech announced that they intend to advance multiple SARS-CoV-2 vaccine candidates into human clinical testing, with the first clinical trials potentially beginning by late April. The two companies began their collaboration focused on developing a vaccine for...